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Abstract
Background Patients with degenerative aortic stenosis
(AS) referred for transcatheter aortic valve implantation
(TAVI) typically have advanced cardiac and vascular
adverse remodeling and multiple comorbidities and,
therefore, might not recover a normal functional capacity
after valve replacement. We sought to investigate the
prevalence, the predictors, and the prognostic impact of
residual impairment of functional capacity after TAVI.
Methods and results Out of 790 patients undergoing TAVI
with impaired functional capacity (NYHA II–IV) at baseline,
NYHA functional class improved in 592 (86.5%) and
remained unchanged/worsened in 92 (13.5%) at follow-up
[median (IQR): 419 (208–807) days] after TAVI. Normal
functional capacity (NYHA I) was recovered in 65.5%
(n = 448) of patients, while the rest had variable degrees of
residual impairment. On multivariable regression analysis,
atrial fibrillation [odds ratio-OR, 2.08 (1.21–3.58),p = 0.008],
low-flow–low-gradient AS [OR, 1.97 (1.09–3.57),
p = 0.026], chronic obstructive pulmonary disease [OR, 1.92
(1.19–3.12), p = 0.008], and lower hemoglobin at baseline
[OR, 1.11 (1.01–1.21) for each g% decrement, p = 0.036]
were independently associated with residual impairment of
functional capacity. All-cause and cardiac mortality were
significantly higher in those with residual impairment of
functional capacity than in those in NYHA I class [hazard ratio-
HR: 2.37 (95% CI: 1.51–3.72), p\0.001 and 2.16 (95% CI:
1.08–4.35), p = 0.030, respectively]. Even mild residual
functional impairment (NYHA II) was associated with a higher
all-cause [HR: 2.02 (95% CI: 1.10–3.72), p = 0.023] and
cardiac [HR: 2.08 (95% CI: 1.42–3.07), p\0.001] mortality.
Conclusion Residual impairment of functional capacity is
common after TAVI and is independently associated with
increased mortality. Predictors of residual impairment of
functional status are predominantly patient-rather than
procedure-related.
Keywords Aortic valve stenosis  TAVI  TAVR 
Functional capacity  Quality of life
Introduction
Patients with severe aortic stenosis (AS) typically have
symptoms of heart failure and impaired quality of life and
are subject to increased mortality and escalation of symp-
toms, once they have developed [1].
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Patients with degenerative AS referred for transcatheter
aortic valve implantation (TAVI) typically have advanced
cardiac [2] and vascular [3] adverse remodeling that may
not be completely reversible after valve replacement
[2, 4, 5]. In addition, non-cardiovascular comorbidities are
common in those patients [2]. Therefore, although TAVI
can modify the dismal natural history of severe AS,
restoration of a normal functional capacity may be less
likely to occur. Although the major TAVI pivotal trials
reported similar functional improvement after TAVI vs.
surgical aortic valve replacement (SAVR) [6–8], a recent
meta-analysis of randomized trials of patients at low and
intermediate risks of perioperative mortality showed that
transfemoral TAVI was associated with reduced mortality
but increased incidence of heart failure within 2 years as
compared to SAVR [9].
Consequently, TAVI might remain a futile treatment in
patients who are more concerned with their functional
status than with the risk of death. Given the fact that all
TAVI candidates expect an improvement of their quality of
life after the procedure [10] and that some patients are
more concerned with their functional status than with the
risk of death, it is desirable to know the likelihood, the
predictors, and the prognostic implications of failure to
recover a normal functional capacity after the procedure.
We specifically sought to identify whether residual
impairment of functional capacity is linked to more
advanced cardiopathy and severer symptoms at baseline, to
non-cardiac comorbidities, or to procedural failure.
Methods
The study included consecutive patients enrolled by 22
centers in the Brazilian TAVI registry from January 2008
to January 2015. Patients were considered eligible for
inclusion if they had severe symptomatic AS (of the native
valve or of a degenerated bioprosthetic surgical valve) and
were considered by the heart team as inoperable or at high
surgical risk. Operative mortality risk was estimated using
the logistic European System for Cardiac Operative Risk
Evaluation (EuroSCORE) and the Society of Thoracic
Surgeons Predicted Risk of Mortality (STS-PROM) risk
scores. List of participating centers, details of TAVI-pro-
cedure technical aspects, and adjudication of adverse
events have been previously described elsewhere [11]. The
study protocol complies with the Declaration of Helsinki
and was approved by the ethics committee at each of the
participating centers and all patients provided written
informed consent. A web-based case report form and
remote electronic data monitoring were utilized with an on-
site source document validation performed in a random
sample (one-fifth of all cases). An independent committee
(including a neurologist) adjudicated all events. All end-
points are reported according to the Valve Academic
Research Consortium-2 (VARC-2) criteria [12]. Device
failure was defined as residual transaortic mean pressure
gradient C20 mmHg, greater than mild aortic regurgita-
tion, and/or failure to correctly position a single device into
the proper anatomical location [12].
Symptoms related to AS included: impaired functional
capacity, angina, syncope, and/or pre-syncope [13].
According to the New York Heart Association (NYHA)
functional classification, patients in NYHA class I have a
normal functional capacity and are free from symptoms
attributable to heart disease, and those in NYHA classes II,
III, and IV have mild, moderate, and severe impairments of
functional capacity due to symptoms attributable to heart
disease, respectively [14].
Transfemoral vascular access was the default approach
with the use of alternative approaches (transubclavian,
direct transaortic, and transcarotid) only when the trans-
femoral access was not possible. The decision to choose
between sedative or general anesthesia was left to the
discretion of the operators. All patients underwent
transthoracic echocardiographic (TTE) study at baseline
and were scheduled for TTE during the same admission for
the index procedure (pre-discharge TTE) and for follow-up
at 6 and 12 months and annually thereafter.
Statistical analysis
Quantitative variables are summarized as mean ± SD or
median (interquartile range-IQR) and are compared by
Student t test or Mann-Whitney U test, while categorical
variables are summarized as frequencies and proportions
and are compared with the use of the Chi-square test.
Uni- and multivariable logistic regression analyses were
used to identify the factors potentially associated with
residual impairment of functional capacity. Factors with a
p value \0.10 in univariable analysis were included in a
stepwise multivariable logistic model.
Cumulative survival curves for patients with and with-
out residual impairment of functional capacity were con-
structed using the Kaplan–Meier method and compared
with the log-rank test and Cox-proportional hazards model.
All analyses were performed with SPSS 23 (IBM,
Armonk, NY, USA). All probability values were two-
tailed, and a p value\0.05 was considered significant.
Results
A total of 819 consecutive patients with severe symp-
tomatic AS were included (mean age 81.5 ± 7.3 years;
49% males). Patients were at high surgical risk
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(EuroSCORE, 20.5 ± 14.7; STS score, 10.3 ± 7.8) with a
high burden of comorbidities (chronic kidney disease,
77%; coronary artery disease, 59%; and chronic obstructive
pulmonary disease, 19%). TAVI was preformed predomi-
nantly under general anesthesia (91%) through a trans-
femoral access (93%), and involved implanting a
CoreValve (73%) or a Sapien-XT (24%) device in the
majority of cases.
Before TAVI, 790 patients (96%) had impaired func-
tional capacity [NYHA II in 124 patients (15%), NYHA III
in 436 patients (53%), and NYHA IV in 230 patients
(28%)]. Among patients with impaired functional capacity
(NYHA C II) at baseline, 684 were alive beyond 30 days
post-procedure and available for clinical follow-up [up to
2268 days, median (IQR): 419 (208–807) days]. Out of
those, NYHA functional class improved in 592 (86.5%)
and remained unchanged/worsened in 92 (13.5%) (Sup-
plementary Figure). Ultimately, 65.5% of patients
(n = 448) had recovered a normal functional capacity
(NYHA I), while the rest had variable degrees of residual
impairment. The latter was mild (NYHA II) in 26.5%
(n = 183) and moderate–severe (NYHA III or IV) in 8%
(n = 53).
Characteristics of patients with residual impairment
of functional capacity
The baseline, periprocedural, and follow-up characteristics
in the patients stratified according to the functional status at
follow-up are summarized in a Supplementary Table. All
relevant baseline and periprocedural factors were tested for
association with residual impairment of functional capacity
after TAVI. Table 1 summarizes the univariable and mul-
tivariable predictors.
On multivariable logistic regression analysis, atrial fibril-
lation/flutter [odds ratio-OR, 2.08 (1.21–3.58), p = 0.008],
low-flow–low-gradient AS [OR, 1.97 (1.09–3.57),
p = 0.026], chronic obstructive pulmonary disease [OR, 1.92
(1.19–3.12), p = 0.008], and lower hemoglobin [OR, 1.11
(1.01–1.21) for each g% decrement, p = 0.036] were inde-
pendently associated with residual impairment of functional
capacity after TAVI. Although device failure (mainly driven
by a higher trans-prosthetic valve pressure gradient-Supple-
mentary Table) was associated with residual impairment of
functional capacity in univariable analysis [OR, 1.73
(1.04–2.88), p = 0.034], it was not an independent predictor
in the multivariable analysis.
Table 1 Univariable and multivariable predictors of residual impairment of functional capacity among survivors beyond 30 days after TAVI
Univariate analysis Multivariate analysis
OR Lower 95% CI
for OR
Upper 95% CI
for OR
p OR Lower 95% CI
for OR
Upper 95% CI
for OR
p
Body mass index (kg/m2) at
baseline
0.968 0.935 1.002 0.065 0.958 0.916 1.001 0.054
EuroSCORE at baseline 1.013 1.002 1.024 0.019 1.002 0.986 1.018 0.812
NYHA functional class at baseline 1.269 1.026 1.569 0.028 0.981 0.744 1.293 0.893
Pulmonary hypertension at baseline 1.436 0.992 2.078 0.055 0.853 0.519 1.401 0.531
Atrial fibrillation/flutter at baseline 2.019 1.280 3.186 0.003 2.084 1.213 3.582 0.008
LV posterior wall thickness (mm)
at baseline
0.925 0.852 1.003 0.061 0.950 0.865 1.044 0.288
LV ejection fraction (%) at baseline 0.991 0.980 1.001 0.072 1.000 0.983 1.017 0.984
Transaortic valve mean PG (mmHg)
at baseline
0.989 0.979 0.999 0.035 1.002 0.988 1.016 0.761
Low-flow–low-gradient AS at
baseline
2.285 1.390 3.757 0.001 1.968 1.086 3.568 0.026
Hemoglobin (g%) at baseline 1.112 1.029 1.189 0.010 1.114a 1.008 1.209 0.036
Creatinine clearance (ml/min) at
baseline
0.990 0.982 0.997 0.008 0.995 0.985 1.006 0.387
Chronic obstructive pulmonary
disease at baseline
1.736 1.170 2.575 0.006 1.922 1.186 3.115 0.008
Device failureb 1.730 1.041 2.875 0.034 1.304 0.678 2.505 0.426
Bold values indicate the covriates that are signficantly associated with residual impairment of functional capacity in multivariable regression
analysis
AS aortic stenosis, CI confidence interval, LV left ventricle, NYHA New York Heart association, OR odds ratio
a Odds ratio calculated per 1 g% decrement
b Defined as residual transaortic mean pressure gradient C20 mmHg, greater than mild aortic regurgitation, and/or failure to correctly position a
single device into the proper anatomical location
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Cardiac remodeling in patients with recovered vs.
impaired functional capacity after TAVI
Echocardiographic follow-up was available in 532 patients
and was performed at a median interval of 366 (161–736)
days after TAVI. As shown in Fig. 1, apart from left
ventricular mass index (LVMi) which improved signifi-
cantly in both groups with no between-group difference at
follow-up, reverse cardiac remodeling was less efficient in
patients with residual impairment of functional capacity.
LV diastolic diameter (LVDD), although similar at
baseline, was significantly larger in those with residual
impairment of functional capacity at follow-up (52.8 ± 9.7
vs. 50.4 ± 8.8, p = 0.008). Impaired LV ejection fraction
(LVEF \50%) was significantly less at follow-up as
compared to baseline only in those with NYHA I symp-
toms. Accordingly, although not significantly different at
baseline, the prevalence of impaired LVEF at latest follow-
up was significantly higher in those with residual
impairment of functional capacity (26.4 vs. 16.2%,
p = 0.007). Mitral regurgitation (MR) severity was similar
in both groups at baseline and significantly improved at
latest follow-up in those with NYHA I symptoms (mod-
erate–severe MR, 13% at follow-up vs. 18% at baseline,
p = 0.005) but not in those with residual impairment of
functional capacity (moderate–severe MR, 26% at follow-
up vs. 23% at baseline, p = 0.44). Consequently, MR
severity at follow-up was significantly higher in those with
residual impairment of functional capacity than in those
with NYHA I symptoms (moderate–severe MR, 26% vs.
13%, p\ 0.001).
Mortality in TAVI patients stratified according
to the functional status at follow-up
During the entire follow-up period, all-cause mortality
was significantly higher in those with residual impairment
of functional capacity than in those who recovered a
Fig. 1 Change from baseline to latest follow-up in left ventricular mass index (LVMi), LV diastolic diameter (LVDD), LV ejection fraction
(LVEF), and mitral regurgitation (MR) in patients with recovered vs. impaired functional capacity after TAVI
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normal functional status (32.6 vs. 12.7%, log-rank
p\ 0.001) (Fig. 2a). Similarly, cardiac mortality was
significantly higher in those with impaired functional
capacity (14.4 vs. 5.4%, p\ 0.001) (Fig. 2b). After
adjustment for the aforementioned LV remodeling
markers (LVEF, LVDD, and MR at latest follow-up), the
association between residual impairment of functional
capacity and all-cause mortality [hazard ratio-HR: 2.37
(95% CI: 1.51–3.72), p\ 0.001] and cardiac mortality
[HR: 2.16 (95% CI: 1.08–4.35), p = 0.030] remained
significant.
To explore whether residual mild impairment of
functional capacity (NYHA II) after TAVI can be detri-
mental, survival analysis was repeated after dividing the
patients into three groups; normal (NYHA I), mildly-im-
paired (NYHA II), and moderate–severely impaired
functional capacity (NYHA III or IV). All-cause mortality
was higher in those with mild impairment (26.4%) than in
those who recovered a normal functional capacity [12.7%,
log-rank p\ 0.001, HR: 2.02 (95% CI: 1.10–3.72),
p = 0.023]. Cardiac mortality was also higher in those
with mild impairment (10.4%) than in those who recov-
ered a normal functional capacity [5.4%, log-rank
p = 0.021, HR: 2.08 (95% CI: 1.42–3.07), p\ 0.001]. In
patients who had a residual moderate–severe functional
impairment, mortality was very high (53.7%, with 27.8%
being cardiac) and was significantly higher than those
with mild impairment [all-cause mortality: log-rank
p\ 0.001, HR: 2.57 (95% CI: 1.60–4.11), p\ 0.001;
cardiac death: log-rank p\ 0.001, HR: 3.31 (95% CI:
1.68–6.53), p = 0.001]. Survival curves for the three
groups are displayed in Fig. 3.
Fig. 2 Kaplan–Meier survival curves for all-cause (a) and cardiac (b) death according to the functional status (normal vs. impaired) at follow-up
after TAVI. CI confidence interval, HR hazard ratio
Fig. 3 Kaplan–Meier survival curves for all-cause (a) and cardiac (b) death according to the functional status (normal vs. mildly-impaired vs.
moderate–severely impaired) at follow-up after TAVI. CI confidence interval, HR hazard ratio
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Discussion
In the present study, we found that the majority of AS
patients recover a normal functional status after TAVI
despite the extensive comorbidities and the advanced car-
diopathy they have at baseline. Eighty-seven percent of
patients gained some improvement of their functional sta-
tus (of at least one NYHA class) and moderate–severe
impairment of functional capacity was reduced from 81%
before to 8% after TAVI. Those who remained symp-
tomatic (NYHA II or more), not only had their functional
capacity impaired, but also had an increased risk of all-
cause and cardiac death. The increased risk of mortality
was not confined to those with moderate–severe residual
impairment of functional capacity but also involved those
with mild residual impairment, emphasizing that restora-
tion of a normal functional capacity should be the clinical
objective in TAVI patients. These results also suggest that
this simple tool (NYHA functional classification) which
has long been one of the main criteria for deciding the
timing of intervention for AS [13, 15] can also be used as a
prognostic marker after valve replacement.
Although TAVI penetration and indications are
expanding, there is also an increasing awareness of that
some patients offered this expensive therapy fail to derive a
functional, morbidity, and/or mortality benefit from it [16].
Futility of TAVI, which can be defined as the lack of
survival/functional improvement in the short term
(6 months to 1 year) [16], is still an underestimated prob-
lem. The present study provides that a set of baseline
characteristics of patients who, in spite of TAVI, frequently
fail to recover a normal functional status and to reverse the
adverse cardiac remodeling and who also have an increased
mortality, so that they can be identified and appropriately-
counseled up-front of the procedure.
Assessment of TAVI outcome: patients’ vs.
physicians’ perspectives
The dismal prognosis of symptomatic severe AS if man-
aged conservatively drew the interest to developing prog-
nosis-modifying strategies. TAVI emerged as a prognosis-
modifying intervention with an un-equivocal mortality
benefit compared to conservative management in patients
who cannot undergo surgery [17] and compared to surgical
management in high-risk [8] and intermediate-risk [6, 18]
patients. However, physicians’ and patients’ appraisal of
risks and benefits may differ [19], and symptomatic relief
is, for some patients, a priority. In a study by Hussain et al.,
the majority of patients undergoing SAVR for severe AS
were willing to accept considerably higher risk of periop-
erative death than what is considered by physicians/
guidelines as ‘‘acceptable’’ [20]. Patients who had more
severe symptoms and lower quality of life as well as those
with pulmonary disease, impaired LVEF, or lower
transaortic pressure gradient were more likely to accept a
high/prohibitive risk of perioperative death if a normal
health is likely to be restored after valve replacement [20].
These results emphasize the importance of symptomatic
improvement (vs. mere survival) among the priorities of
AS patients especially those with more severe symptoms.
How much of the response to TAVI is predictable?
In the present study, two cardiac (atrial fibrillation and low-
flow–low-gradient AS) and two non-cardiac (COPD and
anemia) baseline clinical conditions were identified as
independent predictors of impaired functional status after
TAVI. The benefit of identifying these markers during the
decision-making process prior to TAVI is twofold: (1) to
predict the functional outcome and counsel the patient in
light of the lower probability of restoring a normal func-
tional capacity and (2) to stimulate correction of these
conditions when possible knowing that failure to control
these conditions will impair the functional gains from TAVI.
Although not among the independent predictors, two
markers of cardiac hemodynamics (transaortic valve PG and
brain natriuretic peptide) seem to have an added value to the
LVEF in predicting functional status after TAVI (Supple-
mentary Table). This finding is in line with previous studies
that concluded that the indices of LV mechanics other than
the volumetric LVEF (e.g., longitudinal strain [21]) as well
as markers of elevated LV pressure (e.g., brain natriuretic
peptide [22]) are crucial in predicting the functional status in
patients with severe AS. In fact, a ‘‘low-flow’’ status leading
to a low-gradient severe AS reflects the combination of a
small LV cavity, a severe diastolic dysfunction, and an
impaired longitudinal contractility. The combination of both
low transvalvular gradient and low ejection fraction portends
significantly worse outcomes [23, 24]. These data together
might explain why the mere reduction of LVEF at baseline
was not an independent predictor of the functional outcomes
after TAVI, while the combination of reduced LVEF and
relatively low transaortic valve PG was.
Many attempts have been made to improve the pre-
dictability of TAVI outcomes, including the development
of specific TAVI outcome-prediction scores. Although the
inclusion of frailty and functional parameters into the
predictive models has improved their performance as
compared to surgical risk models, the accuracy of those
models remain modest [16]. The complexity of the car-
diovascular morbidity in patients with severe degenerative
AS probably plays an important role in this suboptimal
performance of predictive models.
Reduced arterial compliance is an important contributor
to the increased afterload and to the adverse cardiac
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remodeling in AS patients [25]. This arterial component of
the AS disease complex is likely even more pronounced in
TAVI candidates, who are typically older with multiple
risk factors for atherosclerosis, than SAVR candidates. In
AS patients referred for valve replacement, a higher arterial
stiffness correlates with less LV mass regression and with
more adverse cardiac events after SAVR [26] and TAVI
[27]. Yotti et al. [4] studied arterial function before and
after TAVI and reported an increase in arterial load after
the procedure resulting in a residual elevation of LV
pressure in 70% of patients. Moreover, myocardial
response to AS involves variable degrees of myocardial
fibrosis [28], the extent of which correlates with NYHA
functional class at baseline [29], and predicts the
improvement in NYHA class after valve replacement [29].
Arterial stiffness and myocardial fibrosis are two examples
of important contributors to the impaired cardiac perfor-
mance in AS patients that might attenuate the benefit from
TAVI. Therefore, the classic screening of patient’s symp-
toms, comorbidities and valvular/myocardial function
might not reflect the complete spectrum of the actual
patient morbidity.
Limitations
This study has a number of limitations. Echocardiographic
data were reported by the treating centers without inde-
pendent core lab adjudication and follow-up echocardio-
graphic data were missing in some cases.
The list of predictors of functional recovery after TAVI
that has been investigated in the present analysis included
valvular and cardiac function, as well as major comor-
bidities. However, markers of frailty and surrogates for
arterial function and myocardial fibrosis were not included
in our analysis. In addition, the socioeconomic and edu-
cational status of the patient as well as the involvement in
regular exercise or rehabilitation programs might also play
a role in determining the functional outcome of these
patients. For future studies, we suggest to study the relation
of those factors to the functional recovery after TAVI.
Clinicians assign a given patient to an NYHA class on
the basis of their subjective interpretation of reported
symptoms, and accordingly, interobserver variability of the
functional assessment is a potential downside of this clas-
sification. In spite of this limitation, a higher NYHA class
was shown in the present study to be a marker of objective
adverse cardiac remodeling and, more importantly, of a
higher mortality risk. It turns out that, in spite of its limi-
tations, this simple tool that is still used to decide the
timing of intervention (as recommended by clinical prac-
tice guidelines) can still be crucial in post-TAVI clinical
assessment. Other more objective, more quantitative, and
purely patient-reported multidimensional assessment tools
have been suggested as better indices of the quality of life.
These multidimensional tools (e.g., EuroQol-5L and SF-36
questionnaires) involve dimensions that are more deter-
mined by the extra-cardiac morbidities and general frailty
(e.g., pain/discomfort, anxiety/depression, and independent
self-care). TAVI that effectively relieves AS and its rele-
vant symptoms and improves survival cannot reverse non-
cardiac pathologies that profoundly impacts on the
patient’s overall quality of life. Previous studies revealed
that the general health status visual analog scale improves
after TAVI by only 2.7–7.0% (mainly driven by
improvements in mobility and usual activity dimensions,
while the other dimensions showed only very modest
change) [30] and that the EQ-5D index also shows a
modest improvement (?7% at 1 year) [31].
Conclusion
The majority of AS patients recover a normal functional
status after TAVI despite the extensive comorbidities and
the advanced cardiopathy they have at baseline. However,
in a sub-group of patients, some degree of functional
impairment persists and portends a diminished reverse
cardiac remodeling and a lower survival. Chronic lung
disease, anemia, atrial fibrillation, and a low-flow–low-
gradient AS are baseline characteristics of this group of
patients.
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